CN1277552C - 五味牵牛胶囊及其制备工艺 - Google Patents
五味牵牛胶囊及其制备工艺 Download PDFInfo
- Publication number
- CN1277552C CN1277552C CNB200410073299XA CN200410073299A CN1277552C CN 1277552 C CN1277552 C CN 1277552C CN B200410073299X A CNB200410073299X A CN B200410073299XA CN 200410073299 A CN200410073299 A CN 200410073299A CN 1277552 C CN1277552 C CN 1277552C
- Authority
- CN
- China
- Prior art keywords
- squama manis
- kaladana
- ingredients
- volatile oil
- containing capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000004615 ingredient Substances 0.000 title claims description 11
- 238000000034 method Methods 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 238000012856 packing Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 241000283956 Manis Species 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 229950005162 benexate Drugs 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 abstract description 13
- 201000007094 prostatitis Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 210000002307 prostate Anatomy 0.000 abstract description 3
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000007779 soft material Substances 0.000 abstract description 2
- 240000001549 Ipomoea eriocarpa Species 0.000 abstract 2
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 abstract 2
- 241000283966 Pholidota <mammal> Species 0.000 abstract 2
- 241000196324 Embryophyta Species 0.000 abstract 1
- 240000006927 Foeniculum vulgare Species 0.000 abstract 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种五味牵牛胶囊是由牵牛子、穿山甲等五种中药材制成的治疗前列腺增生症和慢性前列腺炎的中成药制剂，其加工由穿山甲制粉、小茴香提取挥发油并包和、其余中草药煎煮后浓缩清膏、混制软材、过筛制粒、烘干装囊等工艺组成，其制剂生产成本低廉，加工工艺简便，质量稳定，无毒副作用，口服方便，疗效突出。
Description
所属技术领域
本发明五味牵牛胶囊及其制备工艺属纯中药复方制剂，尤其涉及治疗前列腺增生症和慢性前列腺炎纯中药制剂及其制备工艺。
背景技术
前列腺增生症和慢性前列腺炎是最常见的威胁男性健康的疾病。前列腺增生症又称前列腺肥大，是男性老年病，40岁以上男子病理上均有不同程度的前列腺增生，50岁以后才逐渐出现症状，发病率随年龄而逐渐增加。随着我国人民生活水平和健康水准不断提高，医疗条件的不断改善，居民的平均寿命相应延长，本病的发病率显著升高。据国内统计资料，50岁以上的老年人36～38％有前列腺增生。由于前列腺增生引起尿路梗阻，排尿不利，其中60％可出现急性尿潴留，直接威胁肾功能，对患者的生活和健康带来严重的危害。前列腺增生症约占泌尿外科住院病人的8～11％，仅次于尿路结石而居第二位。慢性前列腺炎则是更为常见和多发的男性病，占泌尿外科男性患者的35～40％，多发于20～40岁的青壮年。被世界卫生组织称为“21世纪病”。目前一般将慢性前列腺炎分为细菌性和无菌性两类，但无论细菌性和无菌性两者都有慢性前列腺炎的症状和体征，前列腺都有一定的异常改变，且发病缓慢、症状多样、临床疗效欠佳，以致病程迁延、经久难愈，甚至导致阳痿、不育等许多继发疾病，给患者造成很大的精神压力甚至悲观失望。
前列腺增生症和慢性前列腺炎作为慢性病、疑难病，不少医家都进行了理论与临床探索，但是，明确前列腺增生症和慢性前列腺炎属于本虚而标实，但以标实为主，且以下焦湿热积滞，肝经痰气瘀阻，壅塞胞内为主要病机的报道尚未见到，由于前列腺增生症的患者年龄偏大，而且往往伴有心、脑、肾等疾病，所以有很大一部分患者不能进行手术治疗。保守治疗有雌激素疗法、α肾上腺能受体阻滞剂疗法(如竹林胺)以及局部注射疗法等效果均难尽如人意，为针对下焦湿热积滞，肝经痰气瘀阻，壅塞胞内为主要病机的前列腺增生症和慢性前列腺炎的新型中成药提供了很大市场。
发明内容
本发明的目的是：选用五种中药材组成组方，生产加工成具有泻湿热、化痰瘀、理气通便功能的复方中药胶囊，用于口服，治疗前列腺增生症和慢性前列性炎，并达到安全、有效、生产成本低廉、无毒副作用。
为了实现上述目的，本发明五味牵牛胶囊及其制备工艺采取的技术方案是：五味牵牛胶囊组方药由27.6％牵牛子、13.8％穿山甲、13.8％川楝子、27.6％黄芪、13.8％小茴香和3.4％β-环糊精辅料组成；五味牵牛胶囊的制备工艺是先把穿山甲于60℃烘干后粉碎过筛，取1/2处方量细粉备用；小茴香加水蒸馏，收集挥发油，以β-环糊精包合备用；将黄芪、牵牛子、川楝子、剩余穿山甲与小茴香药渣，加水煎煮3次，合并3次滤液及收集挥发油后的残滤液，减压浓缩至相对密度为1.28～1.30(60℃)的清膏，加入穿山甲细粉，与β-环糊精包合物混匀，制粒，装入0号胶囊，制成1000粒，即得成药，供患者口服。根据传统中药理论，在本方剂中，牵牛子利水通便，祛痰逐饮，除水气虚肿，治痃癖气块为君药；穿山甲活血散结，消痈溃坚，通经脉，消痈肿为臣药；川楝子疏肝泄热，行气止痛，治疝瘕，除痛气，利小便，通大肠，治肾肝气伤，黄芪益气升阳，利水消肿，托毒生肌，助气壮筋骨，长肉补血，益肾气，去肌热，两药共为佐药；小茴香温肾暖肝，行气止痛，除疝气，暖丹田，壮筋骨为使药，诸药协同共奏泻湿热、化痰瘀、理气通便之功能，对证属下焦湿热积滞，肝经痰气瘀阻，有舌苔厚积之前列腺增生症和慢性前列腺炎患者有显著疗效。据中药现代化理论，本制剂中聚穿山甲中多种微量元素和16种游离氨基酸与小茴香中的多种挥发性油和四味中草药中水溶性物质为一体，促进体肠蠕动，抗溃疡，抑菌消炎，促进肝肿蛋白质更新，有效治疗前列腺增生症和慢性前列腺炎，制剂中含有抗微生物的月桂烯、柠檬烯等挥发性油成分，促使制剂质量稳定，保质期长。
本发明五味牵牛胶囊及其制备工艺的有益效果是：配方中五种中药原料来源广泛，价格低廉，均无毒副作用，加工工艺简便，生产成本低廉，质量稳定，口服方便，治疗前列腺增生症和慢性前列腺炎有突出疗效。
具体实施方式
1.五味牵牛胶囊中各组方最佳有效组方量、百分比含量如下表：
| 中药材名称 | 牵牛子 | 穿山甲 | 川楝子 | 黄芪 | 小茴香 | β-环糊精 | 合计 |
| 配方量(克) | 276 | 138 | 138 | 276 | 138 | 34 | 1000 |
| 含量(％) | 27.6 | 13.8 | 13.8 | 27.6 | 13.8 | 3.4 | 100 |
2.五味牵牛胶囊制备工艺：
①取五种中药材筛净除杂后按配方称量备用；
②将穿山甲于60℃烘干后粉碎过80目筛，取一半处方量细粉后与另一半粗粉分别备用；
③把小茴香加5倍水蒸馏，收集挥发油滤过，将滤液和β-环糊精采用饱和水溶液电动搅拌法包合，取包和物与残滤物分别备用；
④把黄芪、牵牛子、川楝子和剩余的穿山甲与小茴香药渣加5倍水煎煮3次，每次1小时，合并3次滤液，加入小茴香残滤物于一体，减压浓缩至相对密度为1.28～1.30(60℃)的清膏备用；
⑤最后将备用穿山甲粉、备用β-环糊精包和物加入备用清膏中混拌均匀，制成软材，并过16目筛制粒，经60℃烘干，装入0号胶囊得成药。
3.用法与用量：口服，一日3次，每次4粒。
Claims (2)
1、一种五味牵牛胶囊，其特征在于原料组成为27.6％牵牛子、13.8％穿山甲、13.8％川楝子、27.6％黄芪、13.8％小茴香和3.4％β-环糊精。
2、如权利要求1所述五味牵牛胶囊的制备工艺，其特征是：先把穿山甲于60℃烘干后粉碎过筛，取1/2处方量细粉备用；小茴香加水蒸馏，收集挥发油，以β-环糊精包合备用；将黄芪、牵牛子、川楝子、剩余穿山甲与小茴香药渣，加水煎煮3次，合并3次滤液及收集挥发油后的残滤液，减压浓缩至60℃时相对密度为1.28～1.30的清膏，加入穿山甲细粉，与β-环糊精包合物混匀，制粒，装入0号胶囊，即得成药。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410073299XA CN1277552C (zh) | 2004-11-22 | 2004-11-22 | 五味牵牛胶囊及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410073299XA CN1277552C (zh) | 2004-11-22 | 2004-11-22 | 五味牵牛胶囊及其制备工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634363A CN1634363A (zh) | 2005-07-06 |
| CN1277552C true CN1277552C (zh) | 2006-10-04 |
Family
ID=34846830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410073299XA Expired - Fee Related CN1277552C (zh) | 2004-11-22 | 2004-11-22 | 五味牵牛胶囊及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1277552C (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100372546C (zh) * | 2005-12-31 | 2008-03-05 | 张强 | 一种治疗前列腺炎的中药制剂及其制备方法 |
-
2004
- 2004-11-22 CN CNB200410073299XA patent/CN1277552C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634363A (zh) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062372A (zh) | 治疗肝胆道系统结石的溶石性中药制剂 | |
| CN102512630B (zh) | 一种治疗胆囊结石的中药组合物 | |
| CN102698207A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
| CN102085299B (zh) | 治疗前列腺炎的中成药物及其制备方法 | |
| CN101485803A (zh) | 一种治疗月经不调及痛经的中药组合物 | |
| CN101406654B (zh) | 治疗臌胀病的口服液 | |
| CN1277552C (zh) | 五味牵牛胶囊及其制备工艺 | |
| CN114028531B (zh) | 一种治疗乳腺癌的药物及其制备方法和应用 | |
| CN101129615A (zh) | 鸡血藤口服液 | |
| CN1218711C (zh) | 治疗勃起功能障碍的中药制剂及其制备方法 | |
| CN103720949B (zh) | 通便肠清胶囊及制备方法 | |
| CN102526664A (zh) | 一种治疗脾胃不和、脘腹胀痛的药物 | |
| CN102366547A (zh) | 一种治疗便秘型褥疮的中药洗剂制备方法 | |
| CN1236804C (zh) | 一种治痔胶囊的制法 | |
| CN100473391C (zh) | 琉璃草的新用途 | |
| CN103977276A (zh) | 治疗放射性膀胱炎的中药胶囊 | |
| CN102247551A (zh) | 一种治疗便秘的药物 | |
| CN1634235A (zh) | 一种治疗结肠炎的药物 | |
| CN1059578C (zh) | 一种治疗胆石症的药物 | |
| CN101129571A (zh) | 夏枯草口服液 | |
| CN100394930C (zh) | 决明子在制备促进排铅作用药品或保健品中的应用 | |
| CN107261029A (zh) | 用于改善疼痛的中药组合物及其制备方法 | |
| CN100413518C (zh) | 治疗肝硬化腹水胶囊及其制备工艺 | |
| CN100493537C (zh) | 一种用于治疗肺结核的中药制剂及其制备方法 | |
| CN120570960A (zh) | 一种治疗类风湿关节炎骨破坏的中药组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061004 Termination date: 20091222 |